The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk’s diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment. The world’s biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month. The new oral treatment, called Rybelsus, stimulates insulin production in patients with type 2 diabetes, the most common form of the disease, and is meant to be taken once a day.

source https://finance.yahoo.com/news/1-u-fda-approves-oral-144909349.html?.tsrc=rss